Article
Multiplexed measurement of variant abundance and activity reveals VKOR topology, active site and human variant impact.
eLife - 1 Sept 2020
Chiasson Melissa A, Rollins Nathan J, Stephany Jason J, Sitko Katherine A, Matreyek Kenneth A, Verby Marta, Sun Song, Roth Frederick P, DeSloover Daniel, Marks Debora S, Rettie Allan E, Fowler Douglas M
Abstract excerpt
Vitamin K epoxide reductase (VKOR) drives the vitamin K cycle, activating vitamin K-dependent blood clotting factors. VKOR is also the target of the widely used anticoagulant drug, warfarin. Despite VKOR's pivotal role in coagulation, its structure and active site remain poorly understood. In addition, VKOR variants can cause vitamin K-dependent clotting factor deficiency or alter warfarin response. Here, we used...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
